scholarly journals Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease

Aging ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 6151-6171 ◽  
Author(s):  
Valérie Fontaine ◽  
Elodie Monteiro ◽  
Mylène Fournié ◽  
Elena Brazhnikova ◽  
Thinhinane Boumedine ◽  
...  
Keyword(s):  
Animal Models ◽  
Macular Degeneration ◽  
Systemic Administration ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Lipofuscin Accumulation ◽  
Age Related

scholarly journals Computational Quantification of Complex Fundus Phenotypes in Age-Related Macular Degeneration and Stargardt Disease

2011 ◽  
Vol 52 (6) ◽  
pp. 2976 ◽  
Author(s):  
Gwenole Quellec ◽  
Stephen R. Russell ◽  
Todd E. Scheetz ◽  
Edwin M. Stone ◽  
Michael D. Abràmoff
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related

scholarly journals Healthcare Cost of Stargardt Disease

2020 ◽  
Author(s):  
Kanza Aziz ◽  
Bonnielin K. Swenor ◽  
Joseph K. Canner ◽  
Mandeep S. Singh
Keyword(s):  
Macular Degeneration ◽  
Healthcare Cost ◽  
Financial Burden ◽  
Age Related Macular Degeneration ◽  
Administrative Claims ◽  
Direct Healthcare Cost ◽  
Stargardt Disease ◽  
Cross Sectional ◽  
Patient Cost ◽  
Age Related

AbstractImportanceStargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail.ObjectiveTo estimate the direct healthcare cost of SD.DesignCross-sectional analysis of healthcare claims.ParticipantsPatients with an ICD-9 diagnosis code of SD, non-exudative age-related macular degeneration (AMD), or bilateral sensorineural hearing loss (SHL).MethodsOutpatient administrative claims data from the IBM® MarketScan® Commercial Claims and Encounters Database from 2010 to 2014 were analyzed.Main Outcome MeasureAnnual per-patient direct healthcare cost.ResultsA total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71) was higher than that of SHL (median: $51.01, IQR: $25.66-$121.66, p <0.001) and AMD (median: $76.20, IQR: $38.00-$164.86, p <0.001). When adjusted for covariates, the annual payment for SD was $47.83 higher than SHL (p<0.001) and $17.34 higher than AMD (p<0.001).Conclusions and RelevanceThere is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.

scholarly journals Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease

2014 ◽  
Vol 57 (18) ◽  
pp. 7731-7757 ◽  
Author(s):  
Christopher L. Cioffi ◽  
Nicoleta Dobri ◽  
Emily E. Freeman ◽  
Michael P. Conlon ◽  
Ping Chen ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Binding Protein ◽  
Age Related Macular Degeneration ◽  
Retinol Binding Protein ◽  
Potential Treatment ◽  
Stargardt Disease ◽  
Design Synthesis ◽  
Retinol Binding Protein 4 ◽  
Age Related

scholarly journals A Comprehensive Survey of Sequence Variation in the ABCA4 (ABCR) Gene in Stargardt Disease and Age-Related Macular Degeneration

2000 ◽  
Vol 67 (4) ◽  
pp. 800-813 ◽  
Author(s):  
Andrea Rivera ◽  
Karen White ◽  
Heidi Stöhr ◽  
Klaus Steiner ◽  
Nadine Hemmrich ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Sequence Variation ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related ◽  
Comprehensive Survey

scholarly journals Studying Age-Related Macular Degeneration Using Animal Models

2014 ◽  
Vol 91 (8) ◽  
pp. 878-886 ◽  
Author(s):  
Erica L. Fletcher ◽  
Andrew I. Jobling ◽  
Ursula Greferath ◽  
Samuel A. Mills ◽  
Michelle Waugh ◽  
...  
Keyword(s):  
Animal Models ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related

Fluorescence Lifetime Patterns of Retinal Pigment Epithelium Atrophy in Patients with Stargardt Disease and Age-Related Macular Degeneration

2019 ◽  
Vol 243 (3) ◽  
pp. 195-206
Author(s):  
Yasmin Solberg ◽  
Chantal Dysli ◽  
Pascal Escher ◽  
Lisa Berger ◽  
Sebastian Wolf ◽  
...  
Keyword(s):  
Retinal Pigment Epithelium ◽  
Macular Degeneration ◽  
Fluorescence Lifetime ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related ◽  
Retinal Pigment Epithelium Atrophy

scholarly journals Central Role of Oxidative Stress in Age-Related Macular Degeneration: Evidence from a Review of the Molecular Mechanisms and Animal Models

2020 ◽  
Vol 2020 ◽  
pp. 1-19 ◽  
Author(s):  
Samuel Abokyi ◽  
Chi-Ho To ◽  
Tim T. Lam ◽  
Dennis Y. Tse
Keyword(s):  
Oxidative Stress ◽  
Animal Models ◽  
Macular Degeneration ◽  
Molecular Mechanisms ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Related Factor ◽  
Vascular Endothelial ◽  
Age Related ◽  
Endothelial Growth Factor

Age-related macular degeneration (AMD) is a common cause of visual impairment in the elderly. There are very limited therapeutic options for AMD with the predominant therapies targeting vascular endothelial growth factor (VEGF) in the retina of patients afflicted with wet AMD. Hence, it is important to remind readers, especially those interested in AMD, about current studies that may help to develop novel therapies for other stages of AMD. This study, therefore, provides a comprehensive review of studies on human specimens as well as rodent models of the disease, to identify and analyze the molecular mechanisms behind AMD development and progression. The evaluation of this information highlights the central role that oxidative damage in the retina plays in contributing to major pathways, including inflammation and angiogenesis, found in the AMD phenotype. Following on the debate of oxidative stress as the earliest injury in the AMD pathogenesis, we demonstrated how the targeting of oxidative stress-associated pathways, such as autophagy and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, might be the futuristic direction to explore in the search of an effective treatment for AMD, as the dysregulation of these mechanisms is crucial to oxidative injury in the retina. In addition, animal models of AMD have been discussed in great detail, with their strengths and pitfalls included, to assist inform in the selection of suitable models for investigating any of the molecular mechanisms.

scholarly journals Mechanism of All-trans-retinal Toxicity with Implications for Stargardt Disease and Age-related Macular Degeneration

2011 ◽  
Vol 287 (7) ◽  
pp. 5059-5069 ◽  
Author(s):  
Yu Chen ◽  
Kiichiro Okano ◽  
Tadao Maeda ◽  
Vishal Chauhan ◽  
Marcin Golczak ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Toxicity ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related

Analysis of the stargardt disease gene (ABCR) in age-related macular degeneration☆

Ophthalmology ◽  
1999 ◽  
Vol 106 (8) ◽  
pp. 1531-1536 ◽  
Author(s):  
Monica A. De La Paz ◽  
Vanessa K. Guy ◽  
Suzanne Abou-Donia ◽  
Ruth Heinis ◽  
Bekki Bracken ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Disease Gene ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document